Barclays PLC Has $3.20 Million Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

Barclays PLC cut its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 28.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 194,470 shares of the company's stock after selling 77,369 shares during the period. Barclays PLC owned approximately 0.16% of Relay Therapeutics worth $3,203,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in Relay Therapeutics by 198.6% in the 3rd quarter. Royal Bank of Canada now owns 1,287 shares of the company's stock worth $29,000 after purchasing an additional 856 shares during the period. Great West Life Assurance Co. Can boosted its stake in Relay Therapeutics by 48.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 2,494 shares of the company's stock worth $79,000 after purchasing an additional 819 shares during the period. CI Investments Inc. acquired a new position in Relay Therapeutics in the 4th quarter worth $44,000. Metropolitan Life Insurance Co. NY boosted its stake in Relay Therapeutics by 15.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,264 shares of the company's stock worth $79,000 after purchasing an additional 706 shares during the period. Finally, Metropolitan Life Insurance Co NY boosted its stake in Relay Therapeutics by 15.5% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 5,264 shares of the company's stock worth $79,000 after purchasing an additional 706 shares during the period.

A number of equities analysts have recently commented on RLAY shares. HC Wainwright reduced their price objective on shares of Relay Therapeutics from $46.00 to $32.00 in a research note on Friday, June 9th. SVB Securities began coverage on shares of Relay Therapeutics in a research note on Tuesday, August 8th. They set an "outperform" rating for the company. Stifel Nicolaus dropped their target price on shares of Relay Therapeutics from $38.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, April 20th. JPMorgan Chase & Co. dropped their target price on shares of Relay Therapeutics from $42.00 to $29.00 and set an "overweight" rating on the stock in a report on Wednesday, April 19th. Finally, Barclays dropped their target price on shares of Relay Therapeutics from $23.00 to $15.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 19th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $26.28.

Get Our Latest Analysis on Relay Therapeutics

Relay Therapeutics stock opened at $10.73 on Monday. Relay Therapeutics, Inc. has a twelve month low of $9.67 and a twelve month high of $33.06. The company's 50-day moving average price is $11.96 and its two-hundred day moving average price is $14.12. The stock has a market cap of $1.31 billion, a P/E ratio of -3.69 and a beta of 1.34.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its earnings results on Tuesday, August 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Relay Therapeutics had a negative return on equity of 37.81% and a negative net margin of 36,562.53%. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.81 million. During the same period in the prior year, the business posted ($0.71) earnings per share. The firm's revenue for the quarter was down 67.4% compared to the same quarter last year. Equities analysts anticipate that Relay Therapeutics, Inc. will post -3.26 earnings per share for the current fiscal year.

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

Want to see what other hedge funds are holding RLAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Relay Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.

While Relay Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.